Cyclacel Pharmaceuticals, Inc. (CYCCP)
NASDAQ: CYCCP · Real-Time Price · USD · Preferred Stock
4.590
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Company Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, epigenetics, and mitosis biology in the United States and the United Kingdom.
Its lead product, Plogosertib or plogo, is a PLK1 inhibitor, in solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial.
The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Cyclacel Pharmaceuticals, Inc.
| Country | Malaysia |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Sing Wong |
Contact Details
Address: Tower 11, Level 10, Avenue 5, No. 8 Kuala Lumpur, 59200 Malaysia | |
| Phone | 60 9 08517 7330 |
| Website | cyclacel.com |
Stock Details
| Ticker Symbol | CYCCP |
| Exchange | NASDAQ |
| Stock Type | Preferred Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001130166 |
| CUSIP Number | 23254L207 |
| ISIN Number | US23254L2079 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sing Ee Wong | Chief Executive Officer, President and Executive Director |
| Dr. Brian Schwartz M.D. | Chief Medical Officer |
| Cu Seng Kiu | Executive Director, Chief Financial Officer and Secretary |
| Gill Christie | Director of Human Resources |
| Grace Kim | Investor Relations Executive |